127 related articles for article (PubMed ID: 1977229)
1. Hyperprolactinaemia--a clinical study with special reference to long-term follow-up, treatment with dopamine agonists, and pregnancy.
Rasmussen C
Ups J Med Sci; 1990; 95(1):1-29. PubMed ID: 1977229
[No Abstract] [Full Text] [Related]
2. Long-term radiographic follow-up of the sella turcica in hyperprolactinaemic women.
Rasmussen C; Larsson SG; Bergh T
Aust N Z J Obstet Gynaecol; 1990 Aug; 30(3):257-64. PubMed ID: 2256866
[TBL] [Abstract][Full Text] [Related]
3. The effects of CV205-502 in patients with hyperprolactinaemia intolerant and/or resistant to bromocriptine.
Razzaq R; O'Halloran DJ; Beardwell CG; Shalet SM
Horm Res; 1993; 39(5-6):218-22. PubMed ID: 7906243
[TBL] [Abstract][Full Text] [Related]
4. A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205-502, with bromocriptine in women with hyperprolactinaemia.
Homburg R; West C; Brownell J; Jacobs HS
Clin Endocrinol (Oxf); 1990 May; 32(5):565-71. PubMed ID: 1973085
[TBL] [Abstract][Full Text] [Related]
5. The management of hyperprolactinaemia.
Tan SL; Morris D; Jacobs HS
Singapore Med J; 1986 Jun; 27(3):190-5. PubMed ID: 3764453
[No Abstract] [Full Text] [Related]
6. Quinagolide--a valuable treatment option for hyperprolactinaemia.
Barlier A; Jaquet P
Eur J Endocrinol; 2006 Feb; 154(2):187-95. PubMed ID: 16452531
[TBL] [Abstract][Full Text] [Related]
7. Bromocriptine-induced regression of a suprasellar extending prolactinoma during pregnancy.
Bergh T; Nillius SJ; Enoksson P; Wide L
J Endocrinol Invest; 1984 Apr; 7(2):133-6. PubMed ID: 6725868
[TBL] [Abstract][Full Text] [Related]
8. The effect of two dopaminergic drugs on menstrual function and psychological state in hyperprolactinemia.
Lappöhn RE; van de Wiel HB; Brownell J
Fertil Steril; 1992 Aug; 58(2):321-7. PubMed ID: 1353028
[TBL] [Abstract][Full Text] [Related]
9. Effects of bromocriptine-induced pregnancy on prolactin-secreting pituitary tumours.
Bergh T; Nillius SJ; Larsson SG; Wide L
Acta Endocrinol (Copenh); 1981 Nov; 98(3):333-8. PubMed ID: 7293665
[TBL] [Abstract][Full Text] [Related]
10. Return of menstruation and normalization of prolactin in hyperprolactinemic women with bromocriptine-induced pregnancy.
Rasmussen C; Bergh T; Nillius SJ; Wide L
Fertil Steril; 1985 Jul; 44(1):31-4. PubMed ID: 4007192
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of hyperprolactinemic women treated with bromocriptine.
Corenblum B; Taylor PJ
Fertil Steril; 1983 Nov; 40(5):596-9. PubMed ID: 6628704
[TBL] [Abstract][Full Text] [Related]
12. Prolactin secretion and menstrual function after long-term bromocriptine treatment.
Rasmussen C; Bergh T; Wide L
Fertil Steril; 1987 Oct; 48(4):550-4. PubMed ID: 3653413
[TBL] [Abstract][Full Text] [Related]
13. Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia: a double-blind study.
Verhelst JA; Froud AL; Touzel R; Wass JA; Besser GM; Grossman AB
Acta Endocrinol (Copenh); 1991 Oct; 125(4):385-91. PubMed ID: 1683503
[TBL] [Abstract][Full Text] [Related]
14. Pregnancy in patients presenting with hyperprolactinaemia.
Thorner MO; Edwards CR; Charlesworth M; Dacie JE; Moult PJ; Rees LH; Jones AE; Besser GM
Br Med J; 1979 Sep; 2(6193):771-4. PubMed ID: 519192
[TBL] [Abstract][Full Text] [Related]
15. Computed tomographic demonstration of the effects of bromocriptine on pituitary microadenoma size.
Bonneville JF; Poulignot D; Cattin F; Couturier M; Mollet E; Dietemann JL
Radiology; 1982 May; 143(2):451-5. PubMed ID: 7071347
[TBL] [Abstract][Full Text] [Related]
16. Current treatment issues in female hyperprolactinaemia.
Crosignani PG
Eur J Obstet Gynecol Reprod Biol; 2006 Apr; 125(2):152-64. PubMed ID: 16288952
[TBL] [Abstract][Full Text] [Related]
17. Quinagolide efficacy and tolerability in hyperprolactinaemic patients who are resistant to or intolerant of bromocriptine.
Vilar L; Burke CW
Clin Endocrinol (Oxf); 1994 Dec; 41(6):821-6. PubMed ID: 7889620
[TBL] [Abstract][Full Text] [Related]
18. Modern management of prolactinoma.
Reyniak JV
J Reprod Med; 1983 Apr; 28(4):257-63. PubMed ID: 6864668
[TBL] [Abstract][Full Text] [Related]
19. Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerised tomography.
Johnston DG; Hall K; Kendall-Taylor P; Patrick D; Watson M; Cook DB
Lancet; 1984 Jul; 2(8396):187-92. PubMed ID: 6146751
[TBL] [Abstract][Full Text] [Related]
20. The occurrence of macroscopical pituitary calcifications in prolactinomas.
Rasmussen C; Larsson SG; Bergh T
Neuroradiology; 1990; 31(6):507-11. PubMed ID: 2352634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
